questionsmedicales.fr
Phénomènes microbiologiques
Phénomènes physiologiques viraux
Interférence virale
Interférence virale : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Interférence virale : Questions médicales les plus fréquentes",
"headline": "Interférence virale : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Interférence virale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-15",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Interférence virale"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phénomènes physiologiques viraux",
"url": "https://questionsmedicales.fr/mesh/D018406",
"about": {
"@type": "MedicalCondition",
"name": "Phénomènes physiologiques viraux",
"code": {
"@type": "MedicalCode",
"code": "D018406",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G06.920"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Interférence virale",
"alternateName": "Viral Interference",
"code": {
"@type": "MedicalCode",
"code": "D014762",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jocelyne Piret",
"url": "https://questionsmedicales.fr/author/Jocelyne%20Piret",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Guy Boivin",
"url": "https://questionsmedicales.fr/author/Guy%20Boivin",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Shou-Wei Ding",
"url": "https://questionsmedicales.fr/author/Shou-Wei%20Ding",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Plant Pathology, University of California, Riverside, Riverside, CA, USA. Electronic address: shou-wei.ding@ucr.edu."
}
},
{
"@type": "Person",
"name": "Ke Li",
"url": "https://questionsmedicales.fr/author/Ke%20Li",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Daniel M Weinberger",
"url": "https://questionsmedicales.fr/author/Daniel%20M%20Weinberger",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men.",
"datePublished": "2022-09-17",
"url": "https://questionsmedicales.fr/article/36123046",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5551/jat.63549"
}
},
{
"@type": "ScholarlyArticle",
"name": "Proprotein convertases regulate trafficking and maturation of key proteins within the secretory pathway.",
"datePublished": "2022-11-18",
"url": "https://questionsmedicales.fr/article/36707198",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/bs.apcsb.2022.10.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Associated with Disease Activity and Risk of Incident Cardiovascular Disease in Patients with Systemic Lupus Erythematosus.",
"datePublished": "2023-05-06",
"url": "https://questionsmedicales.fr/article/37148453",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10753-023-01821-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors.",
"datePublished": "2023-03-03",
"url": "https://questionsmedicales.fr/article/36980904",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes14030632"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia - A Post-Marketing Survey (J-POSSIBLE).",
"datePublished": "2023-01-11",
"url": "https://questionsmedicales.fr/article/36631082",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1253/circj.CJ-22-0445"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes microbiologiques",
"item": "https://questionsmedicales.fr/mesh/D008827"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénomènes physiologiques viraux",
"item": "https://questionsmedicales.fr/mesh/D018406"
},
{
"@type": "ListItem",
"position": 4,
"name": "Interférence virale",
"item": "https://questionsmedicales.fr/mesh/D014762"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Interférence virale - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Interférence virale",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Interférence virale",
"description": "Comment diagnostiquer l'interférence virale ?\nQuels tests sont utilisés pour l'interférence virale ?\nL'interférence virale peut-elle être détectée cliniquement ?\nQuels marqueurs biologiques indiquent l'interférence ?\nPeut-on utiliser des modèles animaux pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D014762?mesh_terms=Proprotein+Convertase+9&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Interférence virale",
"description": "Quels sont les symptômes de l'interférence virale ?\nL'interférence virale provoque-t-elle des symptômes spécifiques ?\nComment l'interférence affecte-t-elle les symptômes ?\nLes symptômes varient-ils selon le virus ?\nL'interférence virale peut-elle masquer des symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D014762?mesh_terms=Proprotein+Convertase+9&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Interférence virale",
"description": "Comment prévenir l'interférence virale ?\nLes mesures d'hygiène aident-elles à prévenir l'interférence ?\nLes campagnes de vaccination sont-elles efficaces ?\nFaut-il éviter les contacts avec des personnes malades ?\nLes traitements préventifs sont-ils disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D014762?mesh_terms=Proprotein+Convertase+9&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Interférence virale",
"description": "Quels traitements sont efficaces contre l'interférence virale ?\nLes antiviraux aident-ils en cas d'interférence ?\nPeut-on utiliser des vaccins pour prévenir l'interférence ?\nComment gérer les complications liées à l'interférence ?\nLes traitements immunomodulateurs sont-ils efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D014762?mesh_terms=Proprotein+Convertase+9&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Interférence virale",
"description": "Quelles complications peuvent survenir avec l'interférence virale ?\nL'interférence virale peut-elle aggraver des maladies existantes ?\nComment surveiller les complications potentielles ?\nLes complications sont-elles prévisibles ?\nQuels facteurs augmentent le risque de complications ?",
"url": "https://questionsmedicales.fr/mesh/D014762?mesh_terms=Proprotein+Convertase+9&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Interférence virale",
"description": "Quels sont les principaux facteurs de risque d'interférence virale ?\nL'environnement joue-t-il un rôle dans l'interférence ?\nLes antécédents médicaux influencent-ils le risque ?\nLe mode de vie affecte-t-il le risque d'interférence ?\nLes voyages augmentent-ils le risque d'interférence virale ?",
"url": "https://questionsmedicales.fr/mesh/D014762?mesh_terms=Proprotein+Convertase+9&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'interférence virale ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests virologiques et l'observation des interactions virales."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour l'interférence virale ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests PCR et des cultures cellulaires sont souvent utilisés pour détecter l'interférence."
}
},
{
"@type": "Question",
"name": "L'interférence virale peut-elle être détectée cliniquement ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes atypiques peuvent indiquer une interférence virale lors d'infections."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques indiquent l'interférence ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux d'anticorps ou de cytokines peuvent signaler une interférence virale."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des modèles animaux pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des modèles animaux sont souvent utilisés pour étudier l'interférence virale."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'interférence virale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure fièvre, fatigue, et manifestations respiratoires."
}
},
{
"@type": "Question",
"name": "L'interférence virale provoque-t-elle des symptômes spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes sont souvent non spécifiques et varient selon les virus impliqués."
}
},
{
"@type": "Question",
"name": "Comment l'interférence affecte-t-elle les symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut atténuer ou aggraver les symptômes d'une infection virale coexistante."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le virus ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent des virus en interaction et de l'état immunitaire de l'hôte."
}
},
{
"@type": "Question",
"name": "L'interférence virale peut-elle masquer des symptômes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut masquer des symptômes d'autres infections virales, rendant le diagnostic difficile."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'interférence virale ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination et l'hygiène personnelle sont essentielles pour réduire le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les mesures d'hygiène aident-elles à prévenir l'interférence ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mesures d'hygiène rigoureuses peuvent réduire la transmission des virus."
}
},
{
"@type": "Question",
"name": "Les campagnes de vaccination sont-elles efficaces ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles réduisent l'incidence des infections virales et donc le risque d'interférence."
}
},
{
"@type": "Question",
"name": "Faut-il éviter les contacts avec des personnes malades ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les contacts avec des personnes infectées peut réduire le risque d'interférence."
}
},
{
"@type": "Question",
"name": "Les traitements préventifs sont-ils disponibles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements préventifs existent, mais leur utilisation dépend des virus en circulation."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces contre l'interférence virale ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique; la gestion des symptômes est essentielle."
}
},
{
"@type": "Question",
"name": "Les antiviraux aident-ils en cas d'interférence ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antiviraux peuvent être utiles, mais leur efficacité dépend des virus impliqués."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des vaccins pour prévenir l'interférence ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccins peuvent réduire le risque d'infection, mais ne préviennent pas toujours l'interférence."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'interférence ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche symptomatique et un suivi médical."
}
},
{
"@type": "Question",
"name": "Les traitements immunomodulateurs sont-ils efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent aider à réguler la réponse immunitaire, mais leur efficacité varie selon les cas."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'interférence virale ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications respiratoires et neurologiques peuvent survenir en cas d'interférence."
}
},
{
"@type": "Question",
"name": "L'interférence virale peut-elle aggraver des maladies existantes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut exacerber des maladies chroniques comme l'asthme ou la BPCO."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications potentielles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier est crucial pour détecter et gérer les complications."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévisibles, surtout chez les patients à risque."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les maladies sous-jacentes et l'immunodépression augmentent le risque."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'interférence virale ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'immunodépression, l'âge avancé et les infections coexistantes."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle dans l'interférence ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des environnements surpeuplés ou insalubres augmentent le risque d'infections virales."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies respiratoires ou virales augmentent le risque d'interférence."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque d'interférence ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les voyages augmentent-ils le risque d'interférence virale ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyages dans des zones à forte incidence virale peuvent accroître le risque d'infection."
}
}
]
}
]
}
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the i...
Community-dwelling Japanese men (n=622) aged 46-82 years without a history of cardiovascular disease and lipid-lowering medications were included. Serum PCSK9 concentration and CAC score were measured...
The average age, LDL-C, and median serum PCSK9 concentration were 68 years, 122 mg/dL, and 240 ng/mL, respectively. After multivariable adjustment for traditional cardiovascular risk factors, no signi...
A higher serum PCSK9 concentration was associated with a higher CAC prevalence in men aged <60 years, which was independent of traditional cardiovascular risk factors....
Proprotein Convertases (PCs) are serine endoproteases that regulate the homeostasis of protein substrates in the cell. The PCs family counts 9 members-PC1/3, PC2, PC4, PACE4, PC5/6, PC7, Furin, SKI-1/...
To study the relationship of serum PCSK9 and disease activity and major adverse cardiovascular events (MACEs) in systemic lupus erythematosus (SLE). Consecutive patients who fulfilled ≥ 4 ACR criteria...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has an important function in the regulation of lipid metabolism. PCSK9 reduces hepatic low-density lipoprotein receptors, thereby increasing low-d...
This study evaluated the safety and effectiveness of alirocumab in Japanese patients with familial hypercholesterolemia (FH) or non-FH in a real-world clinical setting.Methods and Results: This post-m...
Alirocumab was well tolerated and showed effectiveness in Japanese patients with hypercholesterolemia in a real-world clinical setting....
To examine the safety of proprotein convertase subtilisinekexin type 9 (PCSK9) inhibitors in patients with diabetes, specifically focusing on their impact on glucose metabolism....
Patients with diabetes often require intensified lipid-lowering therapy. PCSK9 inhibitors can reduce low-density lipoprotein cholesterol (LDL-C) concentrations by approximately 60%, and significantly ...
Although the majority of patients with diabetes are undergoing background statin therapy, which may mask potential adverse effects of PCSK9 inhibitors on glycaemic control, current data suggest that t...
In addition to proatherogenic properties, lipoprotein (a) (Lp(a)) has also pro-inflammatory, antifibrinolytic and prothrombogenic features. The aim of the current study was to identify the predictors ...
Seventy-six post-myocardial infarction patients with high Lp(a) levels were included in the study. Ultrasound measurements of flow-mediated dilation of brachial artery (FMD), carotid intima-media thic...
In linear regression model FMD significantly correlated with age at first myocardial infarction (β = 0.689; p = 0.022), high-sensitivity C-reactive protein (β = -1.200; p = 0.009), vascular cell adhes...
Our results suggest that age, systolic blood pressure, Lp(a) levels and other biochemical markers associated with Lp(a) are predictors of functional and morphological properties of the arterial vessel...
The protocol for this study was registered with clinicaltrials.gov on November, 3 2020 under registration number NCT04613167....
Despite being the most common treatment strategy in the management of atherosclerosis and subsequent cardiovascular disease, classical statin therapy has certain disadvantages, including numerous side...
Cardiovascular disease (CVD) complications have remained a major cause of death among patients with diabetes. Hence, there is a need for effective therapeutics against diabetes-induced CVD complicatio...
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a factor accelerating the degradation of LDL receptors, was associated with a gender-dependent risk for cardiovascular (CV) events in the general...
The study enrolled 1188 dialysis patients from the Prospective Registry of The Working Group of Epidemiology of Dialysis Region Calabria (PROGREDIRE) cohort. PCSK9 was measured by colorimetric enzyme-...
During a median 2.9-year follow-up, out of 494 deaths, 278 were CV-related. In unadjusted analyses, PCSK9 levels correlated with increased all-cause (HR...
PCSK9 levels are unrelated to all-cause mortality in haemodialysis patients but, like in studies of the general population, independently of other risk factors, entail a doubling in the risk of CV eve...